注射用头孢哌酮钠舒巴坦钠的不良反应分析

目的分析注射用头孢哌酮钠舒巴坦钠的临床应用价值和不良反应发生的相关要素,以此为临床用药提供合理参考。方法通过回顾性形式对本院于2016年3月-2017年4月期间,收集的102例注射用头孢哌酮钠舒巴坦钠报告进行记录。结果基线资料分析中,头孢哌酮钠舒巴坦钠导致不良反应患者年龄75~89岁占比最高,占38.23%;用药因素多为呼吸系统病症(75.54%),而后为腹腔内部感染(9.80%)、泌尿系统感染(5.88%)、皮肤感染以及软组织损伤(4.90%)、骨骼和关节感染(2.9%)、败血症(0.98%);102例不良反应分析中,皮肤和附件伤害发生率最高(47.08%),而后为血液系统伤害(21.56%)、胃肠部伤害(9.8%)以及肝胆系统损伤(9.8%);3例为严重的不良反应,其中血小板降低1例、过敏性休克2例。结论注射用头孢哌酮钠舒巴坦钠导致的不良反应和化学反应、患者本身体质、饮食情况以及联合用药有一定关联,强化注射用头孢哌酮钠舒巴坦钠的合理性,能够增强临床效果,降低不良反应发生率。

Analysis of Adverse Reactions of Cefoperazone Sodium and Sulbactam Sodium for Injection

Objective To analyze the clinical application value of cefoperazone sodium and sulbactam sodium for injection and the related factors of adverse reactions, so as to provide a reasonable reference for clinical drug use. Methods A total of 102 cases of cefoperazone sodium and sulbactam sodium for injection were collected from our hospital from March 2016 to April 2017 in a retrospective manner. Results In the analysis of baseline data, cefoperazone sodium and sulbactam sodium had the highest incidence of adverse reactions in patients aged 75~89 years. accounting for 38.23%;the drug-related factors were mostly respiratory diseases(75.54%), followed by intra-abdominal infection(9.80%), urinary tract infection(5.88%), and skin. Infection and soft tissue injury(4.90%), bone and joint infection(2.9%), sepsis(0.98%);102 cases of adverse reaction analysis, skin and attachment injury rate was the highest(47.08%), and then blood system damage(21.56%), gastrointestinal injury(9.8%) and hepatobiliary system injury(9.8%);43 cases were serious adverse reactions, including 1 case of thrombocytopenia and 2 cases of anaphylactic shock. Conclusion The adverse reactions and chemical reactions caused by cefoperazone sodium and sulbactam sodium for injection have a certain correlation with the patient’s physical condition, diet and combination. Strengthening the rationality of cefoperazone sodium and sulbactam sodium for injection can enhance clinical effects and reduce adverse reactions Incidence.